FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2624688081> ?p ?o ?g. }

• W2624688081 abstract "ABSTRACT Pyrazinamide is used in the treatment of tuberculosis (TB) because its sterilizing effect against tubercle bacilli allows the shortening of treatment. It is part of standard treatment for drug-susceptible and drug-resistant TB, and it is being considered as a companion drug in novel regimens. The aim of this analysis was to characterize factors contributing to the variability in exposure and to evaluate drug exposures using alternative doses, thus providing evidence to support revised dosing recommendations for drug-susceptible and multidrug-resistant tuberculosis (MDR-TB). Pyrazinamide pharmacokinetic (PK) data from 61 HIV/TB-coinfected patients in South Africa were used in the analysis. The patients were administered weight-adjusted doses of pyrazinamide, rifampin, isoniazid, and ethambutol in fixed-dose combination tablets according to WHO guidelines and underwent intensive PK sampling on days 1, 8, 15, and 29. The data were interpreted using nonlinear mixed-effects modeling. PK profiles were best described using a one-compartment model with first-order elimination. Allometric scaling was applied to disposition parameters using fat-free mass. Clearance increased by 14% from the 1st day to the 29th day of treatment. More than 50% of patients with weight less than 55 kg achieved lower pyrazinamide exposures at steady state than the targeted area under the concentration-time curve from 0 to 24 h of 363 mg · h/liter. Among patients with drug-susceptible TB, adding 400 mg to the dose for those weighing 30 to 54 kg improved exposure. Average pyrazinamide exposure in different weight bands among patients with MDR-TB could be matched by administering 1,500 mg, 1,750 mg, and 2,000 mg to patients in the 33- to 50-kg, 51- to 70-kg, and greater than 70-kg weight bands, respectively." @default.
• W2624688081 created "2017-06-23" @default.
• W2624688081 creator A5013508569 @default.
• W2624688081 creator A5025069184 @default.
• W2624688081 creator A5036624093 @default.
• W2624688081 creator A5056892721 @default.
• W2624688081 creator A5058604069 @default.
• W2624688081 creator A5072683436 @default.
• W2624688081 creator A5090522472 @default.
• W2624688081 date "2017-08-01" @default.
• W2624688081 modified "2023-10-16" @default.
• W2624688081 title "Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis" @default.
• W2624688081 cites W1550111394 @default.
• W2624688081 cites W1593274271 @default.
• W2624688081 cites W1834506558 @default.
• W2624688081 cites W1986157879 @default.
• W2624688081 cites W1986538901 @default.
• W2624688081 cites W1989525615 @default.
• W2624688081 cites W1997433600 @default.
• W2624688081 cites W2004753123 @default.
• W2624688081 cites W2006392678 @default.
• W2624688081 cites W2006583270 @default.
• W2624688081 cites W2011120498 @default.
• W2624688081 cites W2014614108 @default.
• W2624688081 cites W2027132676 @default.
• W2624688081 cites W2033776104 @default.
• W2624688081 cites W2035387023 @default.
• W2624688081 cites W2039786149 @default.
• W2624688081 cites W2040454566 @default.
• W2624688081 cites W2042553471 @default.
• W2624688081 cites W2054018944 @default.
• W2624688081 cites W2063618125 @default.
• W2624688081 cites W2089176235 @default.
• W2624688081 cites W2095551007 @default.
• W2624688081 cites W2098049342 @default.
• W2624688081 cites W2105634155 @default.
• W2624688081 cites W2107834145 @default.
• W2624688081 cites W2120390077 @default.
• W2624688081 cites W2120416054 @default.
• W2624688081 cites W2132162677 @default.
• W2624688081 cites W2140916381 @default.
• W2624688081 cites W2147213334 @default.
• W2624688081 cites W2149849113 @default.
• W2624688081 cites W2155742575 @default.
• W2624688081 cites W2164438043 @default.
• W2624688081 cites W2166113903 @default.
• W2624688081 cites W2493897159 @default.
• W2624688081 cites W2503937174 @default.
• W2624688081 doi "https://doi.org/10.1128/aac.00490-17" @default.
• W2624688081 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5527644" @default.
• W2624688081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28607022" @default.
• W2624688081 hasPublicationYear "2017" @default.
• W2624688081 type Work @default.
• W2624688081 sameAs 2624688081 @default.
• W2624688081 citedByCount "28" @default.
• W2624688081 countsByYear W26246880812017 @default.
• W2624688081 countsByYear W26246880812018 @default.
• W2624688081 countsByYear W26246880812019 @default.
• W2624688081 countsByYear W26246880812020 @default.
• W2624688081 countsByYear W26246880812021 @default.
• W2624688081 countsByYear W26246880812022 @default.
• W2624688081 countsByYear W26246880812023 @default.
• W2624688081 crossrefType "journal-article" @default.
• W2624688081 hasAuthorship W2624688081A5013508569 @default.
• W2624688081 hasAuthorship W2624688081A5025069184 @default.
• W2624688081 hasAuthorship W2624688081A5036624093 @default.
• W2624688081 hasAuthorship W2624688081A5056892721 @default.
• W2624688081 hasAuthorship W2624688081A5058604069 @default.
• W2624688081 hasAuthorship W2624688081A5072683436 @default.
• W2624688081 hasAuthorship W2624688081A5090522472 @default.
• W2624688081 hasBestOaLocation W26246880811 @default.
• W2624688081 hasConcept C112705442 @default.
• W2624688081 hasConcept C126322002 @default.
• W2624688081 hasConcept C142724271 @default.
• W2624688081 hasConcept C176674119 @default.
• W2624688081 hasConcept C2776228421 @default.
• W2624688081 hasConcept C2776967927 @default.
• W2624688081 hasConcept C2777288759 @default.
• W2624688081 hasConcept C2780035454 @default.
• W2624688081 hasConcept C2780459521 @default.
• W2624688081 hasConcept C2781069245 @default.
• W2624688081 hasConcept C71924100 @default.
• W2624688081 hasConcept C98274493 @default.
• W2624688081 hasConceptScore W2624688081C112705442 @default.
• W2624688081 hasConceptScore W2624688081C126322002 @default.
• W2624688081 hasConceptScore W2624688081C142724271 @default.
• W2624688081 hasConceptScore W2624688081C176674119 @default.
• W2624688081 hasConceptScore W2624688081C2776228421 @default.
• W2624688081 hasConceptScore W2624688081C2776967927 @default.
• W2624688081 hasConceptScore W2624688081C2777288759 @default.
• W2624688081 hasConceptScore W2624688081C2780035454 @default.
• W2624688081 hasConceptScore W2624688081C2780459521 @default.
• W2624688081 hasConceptScore W2624688081C2781069245 @default.
• W2624688081 hasConceptScore W2624688081C71924100 @default.
• W2624688081 hasConceptScore W2624688081C98274493 @default.
• W2624688081 hasFunder F4320320671 @default.
• W2624688081 hasFunder F4320338462 @default.
• W2624688081 hasIssue "8" @default.
• W2624688081 hasLocation W26246880811 @default.
• W2624688081 hasLocation W26246880812 @default.

• next